PROVECTUS BIOPHARMACEUTICALS, INC.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 132.3% | 132.3% | -157.7% |
| FY2022 | 57.1% | 57.1% | -174.5% |
| FY2023 | 40.8% | 40.8% | -214.1% |
| FY2024 | 79.4% | 79.4% | -470.3% |
| FY2025 | 86.2% | 86.2% | -778.6% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 132.3% | 132.3% | -157.7% |
| FY2022 | 57.1% | 57.1% | -174.5% |
| FY2023 | 40.8% | 40.8% | -214.1% |
| FY2024 | 79.4% | 79.4% | -470.3% |
| FY2025 | 86.2% | 86.2% | -778.6% |